Truist Securities Maintains Buy on AbbVie, Raises Price Target to $195-Report Released on 5th February 2024
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas maintains a Buy rating on AbbVie (NYSE:ABBV) and raises the price target from $180 to $195 as reported on 5th February 2024.
February 06, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on AbbVie and raises the price target from $180 to $195.
The upgrade in price target by Truist Securities reflects a positive outlook on AbbVie's stock, likely due to strong company fundamentals or expected performance. This analyst endorsement can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100